olaparib

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

olaparib

Trade Name(s):

Lynparza

NCI Definition [1]:

A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

Biomarker-Directed Therapies

Olaparib can be used in the treatment of fallopian tube carcinoma, malignant ovarian neoplasm, primary peritoneal carcinoma, breast carcinoma, and malignant peritoneal neoplasm. BRCA1, BRCA2, and BRCA1 Mutation are the most frequent biomarker inclusion criteria for use of olaparib [2].

Breast Carcinoma +

Fallopian Tube Carcinoma +

Disease is predicted to be sensitive to olaparib: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation

Clinical Setting(s): Maintenance therapy (FDA, NCCN)

Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation	Clinical Setting(s): Maintenance therapy (FDA, NCCN)
	Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy.

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation

Clinical Setting(s): Fourth line of therapy (NICE), Maintenance therapy (SMC), Relapse (BNF)

Note: Neither SMC nor NICE restrict BRCA1/2 alterations to germline mutations.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation	Clinical Setting(s): Fourth line of therapy (NICE), Maintenance therapy (SMC), Relapse (BNF)
	Note: Neither SMC nor NICE restrict BRCA1/2 alterations to germline mutations.

Malignant Ovarian Neoplasm +

Disease is predicted to be sensitive to olaparib: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation

Clinical Setting(s): Maintenance therapy (FDA, NCCN), Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)

Note: Indicated for patients with advanced ovarian cancer (1) with BRCA1/2 deleterious germline mutations who have been treated with three or more prior lines of chemotherapy, and (2) for maintenance treatment with BRCA1/2 deleterious germline or somatic mutations with complete or partial response to first-line chemotherapy.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation	Clinical Setting(s): Maintenance therapy (FDA, NCCN), Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)
	Note: Indicated for patients with advanced ovarian cancer (1) with BRCA1/2 deleterious germline mutations who have been treated with three or more prior lines of chemotherapy, and (2) for maintenance treatment with BRCA1/2 deleterious germline or somatic mutations with complete or partial response to first-line chemotherapy.

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation

Clinical Setting(s): Fourth line of therapy (NICE), Maintenance therapy (SMC), Relapse (BNF)

Note: Neither SMC nor NICE restrict BRCA1/2 alterations to germline mutations.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation	Clinical Setting(s): Fourth line of therapy (NICE), Maintenance therapy (SMC), Relapse (BNF)
	Note: Neither SMC nor NICE restrict BRCA1/2 alterations to germline mutations.

Malignant Peritoneal Neoplasm +

Pancreatic Adenocarcinoma +

Primary Peritoneal Carcinoma +

Disease is predicted to be sensitive to olaparib: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation

Clinical Setting(s): Maintenance therapy (FDA, NCCN)

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation	Clinical Setting(s): Maintenance therapy (FDA, NCCN)
	Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy.

Prostate Carcinoma +

Clinical Trials

View Clinical Trials for olaparib

Olaparib has been investigated in 162 clinical trials, of which 145 are open and 17 are closed. Of the trials investigating olaparib, 5 are early phase 1 (5 open), 26 are phase 1 (18 open), 16 are phase 1/phase 2 (16 open), 91 are phase 2 (83 open), 3 are phase 2/phase 3 (3 open), 19 are phase 3 (18 open), and 2 are phase 4 (2 open).

BRCA1 Loss, BRCA1 Mutation, and BRCA2 Loss are the most frequent biomarker inclusion criteria for olaparib clinical trials.

Breast carcinoma, fallopian tube carcinoma, and ovarian carcinoma are the most common diseases being investigated in olaparib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Olaparib

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Olaparib

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating olaparib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

azd2281, Lynparza, olaparib, azd 2281, azd-2281, olaparib, ku-0059436, olaparib (substance), olaparib (product), parp inhibitor azd2281, parp inhibitor azd2281, 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one

Drug Categories [2]:

PARP inhibitors

Drug Target(s) [2]:

PARP1, PARP2, PARP3

NCIT ID [1]:

C71721

SNOMED ID [1]:

C-7820C

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Biomarker-Directed Therapies

Clinical Trials

Drug Details

References

About

Molecular Medicine

Content Types